SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community chatter focusing on the stock's recent upward momentum, driven by speculation around potential catalysts and technical factors. Some traders point to a possible gamma squeeze and overall market strength, while others express skepticism, citing valuation concerns and mixed fundamentals. The discussion includes debate on whether the rally is sustainable or if a pullback is imminent.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending following its IPO, with the community actively discussing allocation strategies and potential volatility. Initial trading saw a halt, sparking debates about market manipulation and comparisons to other hyped IPOs. Bullish sentiment remains as traders speculate on the stock's potential, while others express concern over its balance sheet.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around aTyr Pharma as it approaches the topline Phase 3 data release for efzofitimod in pulmonary sarcoidosis, driving significant community discussion. While some traders are eyeing a potential pump and dump scenario, others are optimistic about the trial's outcome and future indications, highlighting strong institutional ownership and potential for a short squeeze. The community is closely monitoring for any data leaks and debating the influence of prominent figures on the stock's movement.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential partnerships and integrations, particularly within the Solana ecosystem. Bullish sentiment is fueled by discussions around real-world asset (RWA) adoption and the anticipation of increased volume as more markets open.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to reports suggesting the Trump administration may link COVID-19 vaccines to child deaths, sparking concerns about potential liabilities and renewed scrutiny of vaccine safety data. The community is debating the validity of the reports and the potential impact on vaccine manufacturers, while some investors see the dip as a buying opportunity for the high-dividend stock.  Others believe Pfizer is more than just a vaccine company and should be evaluated as a cancer treatment company.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its acquisition of Oxford Ionics, sparking discussions about the company's future and potential catalysts such as the upcoming Quantum World Congress. Community perspectives are mixed, with some highlighting the acquisition's significance while others express concerns about revenue and valuation. The stock is also being compared to NVDA, with some seeing it as the next big thing in computing.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending due to recent earnings and increased discussion around its potential in AI data center power, with community members highlighting its fast “contract-to-power” deployment. Some are expressing optimism for a continued rally, while others are debating the company's path to profitability and comparing it to sector peers like BE and PLUG. Discussion also includes potential catalysts such as new deals, partnerships, and broader adoption of clean energy initiatives.

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Sonnet BioTherapeutics Holdings Inc

SONN is trending due to news of a business combination to launch a cryptocurrency treasury reserve strategy, causing a premarket surge and high volatility. The community is discussing the potential for a pump and dump, dilution concerns, and the impact of the deal on long-term value for shareholders. The pivot from biotech to crypto has triggered both excitement and skepticism.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending as traders anticipate the closing of its merger with Strive, potentially transforming it into a Bitcoin treasury company; high short interest and borrow fees add to the excitement, with the community debating the impact of potential dilution and the timing of news releases, as well as the possibility of a short squeeze. Despite some volatility, many investors express confidence in the long-term potential, urging others to hold firm.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following news that its Black Widow drone system has been approved for NATO procurement, potentially opening up significant sales opportunities. Community members are actively discussing the implications of this approval, particularly its long-term impact and revenue potential, while also debating the stock's valuation compared to sector peers. Bullish sentiment revolves around the expectation of increased revenues and potential contracts stemming from NATO countries.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CERo Therapeutics Holdings (CERO) announced on Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s lead investigational compound, CER-1236, for Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CERO">CERO stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_10_32_53_AM_png_e724743b98.webp" alt="CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="575" height="64"><figcaption>CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects a "big bounce" for the stock soon.<stembedurl>https://stocktwits.com/pharmdavid13/message/627619560</stembedurl>FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides CERo with the opportunity for increased FDA interactions, potential eligibility for priority review, and the ability to submit data on a rolling basis, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=6780690611361163">said</a>.The new designation comes weeks after the FDA granted the experimental drug an Orphan Drug designation. The FDA's Orphan Drug program is designed to advance the development of drugs that treat rare conditions affecting 200,000 or fewer US patients annually.“These FDA designations are important additional validation with regard to the urgency of the condition as well as the potential that the agency sees in the existing data as submitted. Further, these designations help to decrease the potential time to market and provide additional benefits across the FDA process that are expected to prove both medically and financially valuable,” said CERo Therapeutics CEO Chris Ehrlich.The company is currently undertaking early-stage trials of CER-1236 in patients with acute myeloid leukemia. The study is designed to evaluate the safety and preliminary efficacy of the experimental cancer drug.Shares of the company, however, slumped 12% at the time of writing after the firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1870404/000121390025084610/ea025606902-424b3_cero.htm">said</a> on Thursday that it recently received a letter from the Nasdaq Listing Qualifications department notifying the company that it does not comply with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market.The Nasdaq staff indicated that the company’s securities would be suspended from trading on Nasdaq and delisted on Sept. 8, 2025. The company said that it subsequently requested a hearing to appeal the determination before a panel. The hearing request will stay the suspension of the trading of the company’s common stock and delisting thereof pending such hearing, it said.The company said that it intends to submit a plan to regain compliance with the Stockholders’ Equity Requirement at the hearing. Such a plan of compliance may include an increase in stockholders’ equity through the consummation of public or private financing transactions, the company said, while adding that there can be no assurances that it will obtain a favorable decision from the hearing panel.CERO stock is down by 95% this year and by 97% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/legend-biotech-considering-second-listing-outside-us-report/chwIifbRdqJ">Legend Biotech Considering Second Listing Outside US: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.

Equity

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.


Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA granted orphan drug designation to its lead candidate, CER-1236, for treating acute myeloid leukemia (AML).The stock soared 189% to $19.83&nbsp;in the regular session, but fell by 15% in after-hours trading.The Phase 1/1b, open-label, multi-center clinical trial will assess the safety and initial efficacy of CER-1236 in patients with relapsed or refractory AML, remission with measurable residual disease, or newly diagnosed with TP53-mutated MDS/AML or AML.The study will include a dose escalation to determine the recommended Phase 2 dose and an expansion phase.Major objectives include the frequency of adverse events, dose-limiting toxicities, estimated overall and complete response rates, and measurable residual disease. Minor objectives include pharmacokinetics.The company said CER-1236 is designed to engineer a patient’s T cells to use phagocytic mechanisms — or target-cell “eating” — in addition to T cell destruction mechanisms.The Orphan Drug designation includes FDA assistance in clinical trial design, grants, a waiver of drug application fees, and seven years of market exclusivity upon approval.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they had accumulated shares from $8 to $15 and were still holding 4,700 shares, undecided on whether to carry the position overnight.&nbsp;<stembedurl>https://stocktwits.com/Dansaidso/message/618224240</stembedurl>Another user pointed to the stock's sharp gains, suggesting that after-hours moves were less meaningful for low-float names like Cero, which they believed could see additional upside.<stembedurl>https://stocktwits.com/SK444/message/618231176</stembedurl>Cero stock has declined 83.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'

CER-1236 is designed to engineer T cells with phagocytic, or target-cell "eating," functions alongside traditional cancer-killing mechanisms. 

Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7625589476402466">announced</a> an agreement with the University of California Davis to manufacture its lead compound, CER-1236, which will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia (AML).The company said that the first patient is expected to be dosed in the first half of 2025.CEO Chris Ehrlich highlighted UC Davis’ precision and compliance in manufacturing, which is critical for the successful development and execution of clinical trials.“The manufacturing of product is among the final steps necessary to have completed prior to patient dosing, and we are looking forward to continuing to drive the process forward,” he said.The U.S. Food and Drug Administration (FDA) cleared the company’s application for phase 1 clinical trials of the compound in November.Earlier this month, during a scientific conference in San Diego, the company demonstrated that CER-1236 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=5472816266845157">treated</a> ovarian cancer cells without generating toxicity in animals.On Stocktwits, retail sentiment continues to trend in the ‘bullish’ territory (63/100) while message volume remains high.<figure class="image"><img style="aspect-ratio:811/177;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_101142_png_18b82101f9.webp" alt="CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits" width="811" height="177"><figcaption>CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure>At the end of 2024, the company faced delisting risks after its shares traded below Nasdaq’s minimum bid price requirement. Earlier this year, it announced a one-for-hundred reverse stock split of its common stock to increase its market price.In February, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7680160497345168">raised $5 million</a> through a public offering.<a href="https://stocktwits.com/symbol/CERO">Shares of CERo</a> have dropped by over 80% year-to-date and about 100% in the past 12 months. On Wednesday morning, the stock opened over 2% lower.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish

The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ('CERo') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic...

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

Current Price	$5.44
Prev Close	$5.50
Open	$5.60
Dividend Yield	0.00%
50-Day Moving Average	$7.82
Beta	0.41
Avg. Volume	27,390.57
PE Ratio	-0.02

52-Week High	$895.40
52-Week Low	$4.27
Market Capitalization	$6.63M
EPS (Annual)	-$68.74
Price to Book	-0.65
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

CERO
CERo Therapeutics Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CERO News

CERO CERo Therapeutics Holdings Inc